Xencor Files Registration Statement for Proposed Initial Public Offering

   Xencor Files Registration Statement for Proposed Initial Public Offering

PR Newswire

MONROVIA, Calif., Oct. 11, 2013

MONROVIA, Calif., Oct. 11, 2013 /PRNewswire/ -- Xencor, Inc. today announced
the filing of a registration statement on Form S-1 with the Securities and
Exchange Commission for a proposed initial public offering of shares of its
common stock. All of the shares to be sold in the proposed offering will be
offered by Xencor. The number of shares and price range for the offering have
not been determined. Xencor has applied for a listing of its common stock on
The NASDAQ Stock Market under the symbol "XNCR".

Credit Suisse Securities (USA) LLC and Leerink Swann LLC will act as joint
book-running managers of the offering. Wedbush PacGrow Life Sciences is acting
as a co-manager for the offering. The offering will be made only by means of a
prospectus. A copy of the preliminary prospectus relating to and describing
the terms this offering may be obtained, when available, by contacting Credit
Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison
Avenue, New York, NY 10010, by calling toll-free (800) 221-1037, or by
emailing newyork.prospectus@credit-suisse.com; or Leerink Swann LLC,
Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA,
02110, or by email at Syndicate@Leerink.com, or by phone at 800-808-7525.

A registration statement relating to these securities has been filed with the
Securities and Exchange Commission but has not yet become effective. These
securities may not be sold nor may offers to buy be accepted prior to the time
the registration statement becomes effective.

This press release shall not constitute an offer to sell or a solicitation of
an offer to buy, nor shall there be any sale of these securities in any state
or jurisdiction in which such an offer, solicitation or sale would be unlawful
prior to registration or qualification under the securities laws of any such
state or jurisdiction.

About Xencor
Xencor is a clinical-stage biopharmaceutical company developing engineered
monoclonal antibodies for the treatment of autoimmune diseases, asthma and
allergic diseases, and cancer. Currently, five antibodies are in clinical
development internally and with partners that have been engineered with
Xencor's XmAb® technology. Xencor's internally-discovered programs include
XmAb5871, in Phase 1b/2a clinical trials for the treatment of rheumatoid
arthritis and lupus, XmAb7195 in preclinical development for the treatment of
asthma, and XmAb5574/MOR208 which has been licensed to MorphoSys AG and is in
Phase 2 clinical trials for the treatment of acute lymphoblastic leukemia and
non-Hodgkin lymphoma. Xencor's XmAbantibody engineering technology enables
small changes to the structure of monoclonal antibodies resulting in new
mechanisms of therapeutic action.Xencor partners include Amgen, Merck,
Janssen R&D LLC and Boehringer Ingelheim.

SOURCE Xencor, Inc.

Contact: Jason Spark, Canale Communications for Xencor, +1-619-849-6005,
jason@canalecomm.com
 
Press spacebar to pause and continue. Press esc to stop.